CIPLA | DR. REDDYS LAB | CIPLA/ DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.4 | 24.6 | 131.9% | View Chart |
P/BV | x | 4.0 | 3.8 | 105.5% | View Chart |
Dividend Yield | % | 0.5 | 0.7 | 70.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-22 |
DR. REDDYS LAB Mar-22 |
CIPLA/ DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,083 | 5,614 | 19.3% | |
Low | Rs | 806 | 3,655 | 22.1% | |
Sales per share (Unadj.) | Rs | 269.7 | 1,294.6 | 20.8% | |
Earnings per share (Unadj.) | Rs | 31.7 | 126.9 | 25.0% | |
Cash flow per share (Unadj.) | Rs | 44.8 | 196.9 | 22.7% | |
Dividends per share (Unadj.) | Rs | 5.00 | 30.00 | 16.7% | |
Avg Dividend yield | % | 0.5 | 0.6 | 81.8% | |
Book value per share (Unadj.) | Rs | 257.8 | 1,145.8 | 22.5% | |
Shares outstanding (eoy) | m | 806.81 | 166.43 | 484.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 3.6 | 97.8% | |
Avg P/E ratio | x | 29.8 | 36.5 | 81.6% | |
P/CF ratio (eoy) | x | 21.1 | 23.5 | 89.7% | |
Price / Book Value ratio | x | 3.7 | 4.0 | 90.6% | |
Dividend payout | % | 15.8 | 23.6 | 66.7% | |
Avg Mkt Cap | Rs m | 762,177 | 771,272 | 98.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 35,299 | 38,858 | 90.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 217,633 | 215,452 | 101.0% | |
Other income | Rs m | 3,217 | 4,847 | 66.4% | |
Total revenues | Rs m | 220,851 | 220,299 | 100.3% | |
Gross profit | Rs m | 43,298 | 37,674 | 114.9% | |
Depreciation | Rs m | 10,520 | 11,652 | 90.3% | |
Interest | Rs m | 1,064 | 958 | 111.0% | |
Profit before tax | Rs m | 34,933 | 29,911 | 116.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 9,338 | 8,789 | 106.2% | |
Profit after tax | Rs m | 25,595 | 21,122 | 121.2% | |
Gross profit margin | % | 19.9 | 17.5 | 113.8% | |
Effective tax rate | % | 26.7 | 29.4 | 91.0% | |
Net profit margin | % | 11.8 | 9.8 | 120.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 147,108 | 177,880 | 82.7% | |
Current liabilities | Rs m | 49,129 | 97,658 | 50.3% | |
Net working cap to sales | % | 45.0 | 37.2 | 120.9% | |
Current ratio | x | 3.0 | 1.8 | 164.4% | |
Inventory Days | Days | 63 | 56 | 112.8% | |
Debtors Days | Days | 6 | 113 | 5.1% | |
Net fixed assets | Rs m | 119,415 | 106,819 | 111.8% | |
Share capital | Rs m | 1,614 | 832 | 193.9% | |
"Free" reserves | Rs m | 206,364 | 189,859 | 108.7% | |
Net worth | Rs m | 207,977 | 190,691 | 109.1% | |
Long term debt | Rs m | 4,162 | 5,746 | 72.4% | |
Total assets | Rs m | 266,523 | 284,699 | 93.6% | |
Interest coverage | x | 33.8 | 32.2 | 105.0% | |
Debt to equity ratio | x | 0 | 0 | 66.4% | |
Sales to assets ratio | x | 0.8 | 0.8 | 107.9% | |
Return on assets | % | 10.0 | 7.8 | 129.0% | |
Return on equity | % | 12.3 | 11.1 | 111.1% | |
Return on capital | % | 17.0 | 15.7 | 108.0% | |
Exports to sales | % | 26.2 | 47.1 | 55.7% | |
Imports to sales | % | 8.2 | 18.8 | 43.6% | |
Exports (fob) | Rs m | 57,094 | 101,544 | 56.2% | |
Imports (cif) | Rs m | 17,803 | 40,401 | 44.1% | |
Fx inflow | Rs m | 60,180 | 101,544 | 59.3% | |
Fx outflow | Rs m | 17,803 | 40,401 | 44.1% | |
Net fx | Rs m | 42,376 | 61,143 | 69.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33,259 | 28,108 | 118.3% | |
From Investments | Rs m | -18,719 | -26,387 | 70.9% | |
From Financial Activity | Rs m | -15,998 | -2,422 | 660.5% | |
Net Cashflow | Rs m | -1,323 | 32 | -4,135.0% |
Indian Promoters | % | 13.5 | 26.7 | 50.5% | |
Foreign collaborators | % | 20.1 | 0.0 | - | |
Indian inst/Mut Fund | % | 49.0 | 51.1 | 95.9% | |
FIIs | % | 27.6 | 25.9 | 106.8% | |
ADR/GDR | % | 0.0 | 10.4 | - | |
Free float | % | 66.4 | 62.9 | 105.5% | |
Shareholders | 418,910 | 255,300 | 164.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: SUN PHARMA LUPIN PIRAMAL ENTERPRISES AUROBINDO PHARMA ZYDUS LIFESCIENCES
After opening the day on a flat note, Indian share markets extended gains as the session progressed and ended near day's high.